Information  X 
Enter a valid email address

Verseon Corporation (VERS)

  Print      Mail a friend

Thursday 24 October, 2019

Verseon Corporation

Update on Facility Sale-Leaseback

RNS Number : 0120R
Verseon Corporation
24 October 2019
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (596/2014/EU) ("MAR"). WITH THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

October 24, 2019

 

Verseon Corporation

("Verseon" or the "Company")

 

Update on Sale-Leaseback of Verseon's Research, Development, and Operations Facility

FREMONT, Calif.-Further to the announcement of October 23, 2019, Verseon Corporation (AIM: VERS), a clinical-stage pharmaceutical company, today announces that it will not be in a position to sign the sale-leaseback for its research, development, and operations facility in Fremont, CA, (the "Facility") disclosed in yesterday's announcement ahead of the Annual General Meeting of Shareholders convened for October 28, 2019 ("AGM").

In order to enable the directors of the Company to enter into a sale-leaseback of the Facility and to consider options available to the Company, the resolution relating to the sale-leaseback will remain on the agenda for the AGM. The vote will proceed on the basis that the terms of the final sale-leaseback agreement will be materially similar or better than those announced on October 23, 2019.    

- Ends -

 

For further information, please contact

Verseon Corporation

www.verseon.com

Sebastian Wykeham / Tina Schlafly

+1 (510) 225 9000



Arden Partners (NOMAD and Broker)


Ruari McGirr / Ciaran Walsh / Dan Gee-Summons (Corporate Finance) / Fraser Marshall (Equity Sales)

+44 (0) 20 7614 5900



For trade and pharma media enquiries, please contact

Vane Percy & Roberts


Simon Vane Percy

+44 (0) 1737 821 890

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
UPDCKQDQFBDKDKB

a d v e r t i s e m e n t